Top Therapeutic Vaccines Companies

Global Therapeutic Vaccines Market size was valued at USD 59.35 Billion in 2024 and is poised to grow from USD 65.58 Billion in 2025 to USD 145.77 Billion by 2033, growing at a CAGR of 10.5% during the forecast period (2026–2033). 

Therapeutic vaccine manufacturers should invest heavily in R&D of new vaccines that are more effective than what's currently available in the market. Therapeutic vaccine companies can also collaborate and partner with each other to fast track the development of new vaccines and reduce time-to-market. Mergers and acquisitions are also popular strategies that could help therapeutic vaccine market players maximize their market share and presence. 'GlaxoSmithKline plc (GSK) (United Kingdom) ', 'Sanofi S.A. (France) ', 'Pfizer Inc. (United States) ', 'Moderna, Inc. (United States) ', 'BioNTech SE (Germany) ', 'Bavarian Nordic A/S (Denmark) ', 'Medigene AG (Germany) ', 'Arbutus Biopharma Corporation (Canada) ', 'Inovio Pharmaceuticals, Inc. (United States) ', 'Dynavax Technologies Corporation (United States) ', 'Agenus Inc. (United States) ', 'Heat Biologics, Inc. (United States) ', 'Northwest Biotherapeutics, Inc. (United States) ', 'ImmunoCellular Therapeutics, Ltd. (United States) ', 'Advaxis, Inc. (United States) ', 'OncoSec Medical Incorporated (United States) ', 'Vical Incorporated (United States) ', 'Celldex Therapeutics, Inc. (United States) ', 'Altimmune, Inc. (United States) '

Surge in incidence of infectious and chronic diseases around the world has increased awareness regarding preventive healthcare among people around the world, which in turn, is forecasted to benefit sales of therapeutic vaccines.

Use in Immunotherapy: Therapeutic vaccine vendors can focus on developing new products that can be used in specific immunotherapies to improve the treatment and efficacy rate among cancer patients. Therapeutic vaccine companies can modify immune responses as per tumor and improve the chances of successful immunotherapy.

North America is estimated to account for a substantial share of the global therapeutic vaccines market owing to the presence of a developed healthcare ecosystem and high healthcare expenditure. Growing investments in R&D of novel therapeutic vaccines in this region will also aid the dominance of this region in the global market. The United States is projected to spearhead the demand for therapeutic vaccine in North America followed by Canada across the forecast period and beyond. An established clinical trial and regulatory approval system in the United States helps therapeutic vaccine market growth.